Download citation file:
The approach to hepatitis C virus (HCV) infection has undergone tremendous change in the past 2 years. The first-generation protease inhibitors have been approved for treatment of genotype 1 infection, leading to sustained virologic response (SVR) rates of 68%–75% for treatment-naïve patients (1, 2). Other direct-acting antiviral agents are being developed, and it is expected that treatments for all genotypes will have better response rates and side effect profiles in coming years. In this context, the Centers for Disease Control and Prevention (CDC) recently updated its HCV screening guidelines and now recommends screening for all Americans born between 1945 and 1965 (3) because the baby-boomer generation has the highest prevalence of HCV infection (4). Risks for cirrhosis and hepatocellular carcinoma continue to rise due to progression of HCV infection, and HCV remains the most common indication for liver transplantation. Effective treatment can reduce the risk for these life-threatening complications, and here we discuss HCV prevention, screening, diagnosis, and management (5).
Regimens for treatment-naïve hepatitis C genotype 1.
Regimens for treatment-experienced hepatitis C genotype 1.
Please read the other comments before posting. Contributors must reveal any conflict of interest. Comments are moderated and will appear on the site at the discretion of The American College of Physicians editorial staff. Please be sure your email address is updated in your account, otherwise the American College of Physicians will not be able to contact you about your comment.
* = Required Field
Disclosure of Any Conflicts of Interest* (applies to the past 5 years and foreseeable future) Indicate any potential conflicts of interest of each author below, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, speakers bureau, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents filed, received, or pending). If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Clinical Slide Set. Hepatitis C
Terms of Use
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
to gain full access to the content and tools.
Learn more about subscription options
Customize your page view by dragging & repositioning the boxes below.